Brief: Orchard Therapeutics, Pharming Group Announce Collaboration To Develop And Commercialize Ex Vivo Autologous HSC Gene Therapy For Hereditary Angioedema
01/07/2021 06:07
July 1 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS, PHARMING GROUP ANNOUNCE
COLLABORATION TO
DEVELOP AND COMMERCIALIZE EX VIVO AUTOLOGOUS HSC GENE THERAPY
FOR HEREDITARY ANGIOEDEMA
* CO WILL RECEIVE $17.5 MILLION COMPRISING $10 MILLION IN
CASH AND
A $7.5 MILLION EQUITY INVESTMENT FROM PHARMING
* ELIGIBLE TO RECEIVE UP TO $189.5 MILLION IN DEVELOPMENT,
REGULATORY,SALES MILESTONES & MID-SINGLE TO LOW DOUBLE-DIGIT
ROYALTY PAYMENTS ON SALES
* PHARMING HAS BEEN GRANTED WORLDWIDE RIGHTS TO OTL-105 AND
WILL
BE RESPONSIBLE FOR CLINICAL DEVELOPMENT, REGULATORY FILINGS,
COMMERCIALIZATION
Source text for Eikon: ID:nGNX4DhpsW
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln